Precipio, Inc. PRPO
Set alert
17.79 USD -0.31 -1.71%
At close · Nov 2
17.79 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
17.79 Day range 18.70
17.79 52-week range 33.63
- YTD
- -22.58%
- 1 year
- -13.22%
- Open
- 18.48
- Prev close
- 18.10
- Mkt cap
- 31.85M
- Vol
- 12.36K
- Avg vol
- 105.58K
- EPS
- -0.63
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 17.79
- High
- 18.70
- Forward P/E
- 13.34
- Beta
- 1.42
- Short ratio
- 0.59
- Inst. own
- 8.79%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.13
- 200-d avg
- 5.98
- 1y target
- 0.00
3M chart
Signals (15)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 30, 2026 | 3 days ago |
| RSI: Oversold | Oct 23, 2026 | 1 week ago |
| SMA: Bearish | Sep 23, 2026 | 1 month ago |
| SMA: Bearish | Sep 17, 2026 | 1 month ago |
| SMA: Bullish | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 2, 2026 | 2 months ago |
| RSI: Overbought | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
Key statistics
- Market cap
- 7.71M
- Enterprise value
- 9.10M
- Trailing P/E
- 0.00
- Forward P/E
- 13.34
- PEG ratio
- 0.00
- Price / sales
- 0.46
- Price / book
- 0.51
- EPS (TTM)
- -1.81
- Beta
- 1.42
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -22.90%
- Revenue (TTM)
- 16.72M
- Revenue growth
- 25.70%
- Free cash flow
- -894.75K
- Total cash
- 1.28M
- Total debt
- 1.17M
- Return on equity
- -29.22%
- Shares outstanding
- 1.48M
- Short % of float
- 0.35%
- 50-day average
- 6.13
- 200-day average
- 5.98
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
PRPO Revenue — quarterly 7.02M
PRPO Net income — quarterly -219.00K
PRPO EPS — quarterly -0.12
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | 0.00 | -0.42 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -0.83 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -1.46 | — | — |
| Mar 29, 2024 | Dec 1, 2023 | 0.00 | -0.41 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -1.04 | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | -1.80 | — | — |
About Precipio, Inc.
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- precipiodx.com
News
- Precipio Announces Q3-2026 Shareholder Update Call
- Precipio (NASDAQ:PRPO) Shares Cross Below 200-Day Moving Average – Here’s Why
- Precipio: Management Dreams Big, Institutions Have A Toe In
- Precipio (NASDAQ:PRPO) Share Price Crosses Below 200 Day Moving Average – What’s Next?
- PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?
- Analyzing Precipio (NASDAQ:PRPO) and AdaptHealth (NASDAQ:AHCO)
- Precipio Q2 2026 Earnings Call: Complete Transcript
- PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
- Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong
- Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript
Your note
Sign in to keep a note on PRPO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDREWS RONALD ASBURY | Director | Stock Award(Grant) | Oct 14, 2024 | 11,128 |
| COHEN DAVID SETH | Director | Stock Award(Grant) | Oct 14, 2024 | 47,560 |
| COSSMAN JEFFREY M.D. | Director | Stock Award(Grant) | Oct 14, 2024 | 12,312 |
| DANIELI ILAN | Chief Executive Officer | Purchase | Jan 2, 2023 | 57,046 |
| FISHER DOUGLAS CARL M.D. | Director | Stock Award(Grant) | Oct 26, 2023 | 5,572 |
| LAPORTE KATHLEEN D | Director | Stock Award(Grant) | Apr 14, 2024 | 10,071 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 1.95% | 28,912 | 150.38K | Sep 29, 2024 |
| Vanguard Group Inc | 1.19% | 17,645 | 91.78K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.98% | 14,458 | 75.20K | Sep 29, 2024 |
| Wells Fargo & Company | 0.04% | 550 | 2.86K | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.04% | 611 | 3.18K | Sep 29, 2024 |
| Citigroup Inc. | 0.03% | 470 | 2.44K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 1.19% | 17,645 | 91.78K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.48% | 7,154 | 37.21K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.21% | 3,097 | 16.11K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.13% | 1,879 | 9.77K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 1,752 | 9.11K | Oct 30, 2024 |